Clinical Trial Update: Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With High-Risk or Recurrent Myeloid Leukemia After Undergoing Donor Stem Cell Transplant [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 1/2 study evaluating therapeutic allogeneic lymphocytes with aldesleukin for high-risk or recurrent myeloid leukemi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes
• Myelogenous Leukemia

Drugs mentioned

• Allogeneic lymphocyte therapy
• Proleukin (aldesleukin)

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | Phase 1, Phase 2 | Status: TERMINATED